These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21894433)

  • 21. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
    Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
    Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
    Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines.
    Nishio K; Ishida T; Arioka H; Kurokawa H; Fukuoka K; Nomoto T; Fukumoto H; Yokote H; Saijo N
    Anticancer Res; 1996; 16(6B):3387-95. PubMed ID: 9042196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
    Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
    Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel indication for cancer therapy: Chk1 inhibition sensitizes tumor cells to antimitotics.
    Xiao Z; Xue J; Semizarov D; Sowin TJ; Rosenberg SH; Zhang H
    Int J Cancer; 2005 Jul; 115(4):528-38. PubMed ID: 15688426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Constitutive activation of p70 S6 kinase is associated with intrinsic resistance to cisplatin.
    Dhar R; Basu A
    Int J Oncol; 2008 May; 32(5):1133-7. PubMed ID: 18425342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Checkpoint kinase 1 modulates sensitivity to cisplatin after spindle checkpoint activation in SW620 cells.
    Peralta-Sastre A; Manguan-Garcia C; de Luis A; Belda-Iniesta C; Moreno S; Perona R; Sanchez-Perez I
    Int J Biochem Cell Biol; 2010 Feb; 42(2):318-28. PubMed ID: 19931410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An anti-GD2 monoclonal antibody enhances apoptotic effects of anti-cancer drugs against small cell lung cancer cells via JNK (c-Jun terminal kinase) activation.
    Yoshida S; Kawaguchi H; Sato S; Ueda R; Furukawa K
    Jpn J Cancer Res; 2002 Jul; 93(7):816-24. PubMed ID: 12149148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of cell death and induction of G2 arrest accumulation in human ovarian clear cells by HNF-1β transcription factor: chemosensitivity is regulated by checkpoint kinase CHK1.
    Shigetomi H; Sudo T; Shimada K; Uekuri C; Tsuji Y; Kanayama S; Naruse K; Yamada Y; Konishi N; Kobayashi H
    Int J Gynecol Cancer; 2014 Jun; 24(5):838-43. PubMed ID: 24804869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
    Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
    Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The protein kinase C inhibitor Gö6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints.
    Kohn EA; Yoo CJ; Eastman A
    Cancer Res; 2003 Jan; 63(1):31-5. PubMed ID: 12517773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells.
    Zhou Y; Pan DS; Shan S; Zhu JZ; Zhang K; Yue XP; Nie LP; Wan J; Lu XP; Zhang W; Ning ZQ
    Biomed Pharmacother; 2014 May; 68(4):483-91. PubMed ID: 24721323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinoblastoma tumor suppressor gene expression determines the response to sequential flavopiridol and doxorubicin treatment in small-cell lung carcinoma.
    Budak-Alpdogan T; Chen B; Warrier A; Medina DJ; Moore D; Bertino JR
    Clin Cancer Res; 2009 Feb; 15(4):1232-40. PubMed ID: 19174488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents.
    Zenvirt S; Kravchenko-Balasha N; Levitzki A
    Oncogene; 2010 Nov; 29(46):6149-59. PubMed ID: 20729914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic effects of pyrrolidine dithiocarbamate in small-cell lung cancer cells, alone and in combination with cisplatin.
    Tahata S; Yuan B; Kikuchi H; Takagi N; Hirano T; Toyoda H
    Int J Oncol; 2014 Oct; 45(4):1749-59. PubMed ID: 25070243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells.
    Takeda K; Suyama H; Igishi T; Shigeoka Y; Matsumoto S; Yamasaki A; Hashimoto K; Sumikawa T; Morita M; Ueda Y; Shimizu E
    Oncol Rep; 2008 Apr; 19(4):945-51. PubMed ID: 18357380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiproliferative effects of the histone deacetylase inhibitor FR901228 on small-cell lung cancer lines and drug-resistant sublines.
    Tsurutani J; Soda H; Oka M; Suenaga M; Doi S; Nakamura Y; Nakatomi K; Shiozawa K; Amada YY; Kamihira S; Kohno S
    Int J Cancer; 2003 Mar; 104(2):238-42. PubMed ID: 12569581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
    Bryant C; Rawlinson R; Massey AJ
    BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of the Replication Stress Response Is a Synthetic Vulnerability in SCLC That Acts Synergistically in Combination with Cisplatin.
    Nagel R; Avelar AT; Aben N; Proost N; van de Ven M; van der Vliet J; Cozijnsen M; de Vries H; Wessels LFA; Berns A
    Mol Cancer Ther; 2019 Apr; 18(4):762-770. PubMed ID: 30872379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
    Aoe K; Kiura K; Ueoka H; Tabata M; Chikamori M; Kohara H; Harada M; Tanimoto M
    Anticancer Res; 2004; 24(6):3893-7. PubMed ID: 15736428
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.